SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy

Paola Cassis(Mario Negri Institute for Pharmacological Research), Carla Zoja(Mario Negri Institute for Pharmacological Research)
JCI Insight
August 8, 2018
Cited by 172


Related Papers